Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Core Insights - Tarsus Pharmaceuticals is advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, a significant eye disease with no FDA-approved therapy, with plans to initiate a Phase 2 study in the second half of 2025 [1][2][7] Company Updates - In 2024, Tarsus established XDEMVY as one of the most successful eye care launches, achieving consistent quarter-over-quarter revenue growth and broad payer coverage, with over 104,000 bottles delivered and more than $113 million in net product sales during the first nine months of 2024 [3][7] - The company plans to enhance its strategic initiatives in 2025, focusing on generating new evidence for XDEMVY and pursuing Ocular Rosacea as a transformative opportunity in eye care [3][6] - Tarsus has deployed approximately 50 new sales representatives in Q3 2024, which is expected to positively impact sales in Q4 2024 [7] Product Information - XDEMVY (lotilaner ophthalmic solution, 0.25%) is designed to treat Demodex blepharitis by targeting Demodex mite infestation, with pivotal trials showing significant improvements in key endpoints [10][14] - Ocular Rosacea affects approximately 15-18 million Americans, with TP-04 representing a potential category-creating therapy for this condition [7][12] - The company anticipates potential European regulatory approval for a preservative-free formulation of XDEMVY in 2027 and is working on regulatory pathways in Japan and China for its products [7][14]